Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep

Basheer Ahamad Kummangal; Deependra Kumar; Hruda Nanda Mallick

doi:10.1016/j.bbr.2012.09.015

Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep

Behav Brain Res. 2013 Jan 15:237:59-62. doi: 10.1016/j.bbr.2012.09.015. Epub 2012 Sep 16.

Authors

Basheer Ahamad Kummangal¹, Deependra Kumar, Hruda Nanda Mallick

Affiliation

¹ Department of Physiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. basheer91@gmail.com

PMID: 22989413
DOI: 10.1016/j.bbr.2012.09.015

Abstract

Orexins are important regulators of sleep-wakefulness (S-W). Rats were intracerebroventricularly (ICV) administered selective orexin-2 receptor antagonist, TCS-OX2-29. There was decreased wakefulness due to a decrease in the average wake episode duration and an increased REM sleep due to an increase in the number of REM episodes, indicating an inhibitory role of the central orexin-2 receptors on REM sleep generation.

MeSH terms

Animals
Injections, Intraventricular
Isoquinolines / administration & dosage*
Male
Orexin Receptors
Pyridines / administration & dosage*
Rats
Rats, Sprague-Dawley
Rats, Wistar
Receptors, G-Protein-Coupled / antagonists & inhibitors*
Receptors, G-Protein-Coupled / metabolism
Receptors, Neuropeptide / antagonists & inhibitors*
Receptors, Neuropeptide / metabolism
Sleep, REM / drug effects*
Time Factors
Wakefulness / drug effects

Substances

1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanone
Isoquinolines
Orexin Receptors
Pyridines
Receptors, G-Protein-Coupled
Receptors, Neuropeptide